Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 in Adults With Obesity or Overweight and Comorbidity
2024-513691-18-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing AZD5004 with Placebo (2 arms). Primary endpoints: Percent change in body weight from baseline at Week 26 and Proportion of participants with weight loss ≥ 5% from baseline weight at Week 26. Started Oct 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2024-513691-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513691-18-00.